AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUN 13 - (NewsRx.com & NewsRx.net) -- Biosyn, Inc. announced at the Microbicides 2002 Conference in Antwerp, Belgium, successful results of two clinical studies for Savvy (C31G intravaginal gel), currently in development as a contraceptive and for the prevention of sexually transmitted diseases (STDs).
Presented were results of a phase I/II dose escalation study in which 64 women used Savvy gel in single and multiple doses for 2 weeks. Data from the trial indicated that Savvy met the primary endpoints of safety and acceptability.
Results of the second trial, a phase I/II postcoital testing (PCT) study investigating the safety and spermicidal efficacy of three different concentrations of Savvy, were also presented at the conference. This study also met the primary endpoints of safety and spermicidal ...
Source: HighBeam Research, Biosyn announces positive results for trials of microbicide...